|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.00 HKD | -11.59% |
|
-7.56% | -20.44% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Research, Development, Production and Sale of Biopharmaceutical Products | 23Cr | 84Cr | 452.63Cr | 212.39Cr | 305.63Cr | |||
Total Assets | 480.58Cr | 549.59Cr | 918.11Cr | 1.28TCr | 1.6TCr | |||
Interest Expense | -1.04Cr | -4.33Cr | -8.7Cr | -6.83Cr | -13Cr | |||
Income Tax Expense | - | - | 2L | - | - | |||
CAPEX | -72Cr | -80Cr | -72Cr | -59Cr | -78Cr | |||
EBT | -125.81Cr | -142.22Cr | 194.25Cr | -50Cr | -114.08Cr | |||
Gross Profit | 19Cr | 74Cr | 439.3Cr | 183.49Cr | 240.4Cr | |||
D&A | 5.7Cr | 10Cr | 14Cr | 19Cr | 26Cr | |||
Net Income | -107.49Cr | -116.84Cr | 202.83Cr | -51Cr | -111.3Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Mainland China | 9.7Cr | 84Cr | 159.35Cr | 187.8Cr | 270.03Cr | |||
Total Assets | 165.23Cr | 242.7Cr | 319.88Cr | 364.85Cr | 435.23Cr | |||
United States of America (USA) | 13Cr | - | 293.15Cr | 24Cr | 34Cr | |||
Total Assets | - | - | 29Cr | 40Cr | 32Cr | |||
Total Assets | - | - | - | - | - | |||
Other Regions | - | - | 12.03L | 22.56L | 1.75Cr | |||
Total Assets | 12.46L | 5L | 39T | 18T | 6T |
- Stock Market
- Stocks
- 9926 Stock
- Financials Akeso, Inc.
- Business Segments
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition